P3BEP (ANZUP 1302): An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for individuals aged 11-50 years with intermediate and poor-risk metastatic germ cell tumours (GCTs).
Mak B, Tran B, Thomas H, Pashankar F, Hansen A, Feldman D, Huddart R, Wheater M, Dunwoodie E, Mazhar D, Lawrence N, Stevanovic A, Birtle A, Oladipo O, Wyld D, Balagtas J, Stockler M, Grimison P. P3BEP (ANZUP 1302): An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for individuals aged 11-50 years with intermediate and poor-risk metastatic germ cell tumours (GCTs). Journal Of Clinical Oncology 2025, 43: tps653-tps653. DOI: 10.1200/jco.2025.43.5_suppl.tps653.Peer-Reviewed Original ResearchMetastatic germ cell tumorsGerm cell tumorsProgression free survivalPhase 3 trialTwo-sided type I error rateRandomized trials of chemotherapyRandomized phase 3 trialIndependent data safety monitoring committeeData Safety Monitoring CommitteeResponse rateFirst-line chemotherapyStandard chemotherapy regimensFavorable response rateImprove cure ratesTrials of chemotherapyBaseline blood samplesSafety Monitoring CommitteePost-chemotherapy treatmentStage 1BEP chemotherapyStandard BEPTranslational substudyFree survivalChemotherapy regimensIntermediate-risk
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply